Lantheus Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
Lantheus Holdings, Inc. (LNTH) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2024-02-22
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2023-12-31 was $0.00.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2023-09-30 was $0.00.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2022-12-31 was $0.00.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2022-09-30 was $0.00.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2023 was $0.00.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2022 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |